Pfizer In The Dock
Florida’s lawsuit should prompt Australia to examine what we were told, what was known, and who must answer.
Florida’s lawsuit should prompt Australia to examine what we were told, what was known, and who must answer.
Australians were expected to make life-changing decisions about COVID vaccination on the strength of assurances from politicians, health officials and pharmaceutical companies.
Those assurances deserve scrutiny every bit as serious as the demands placed on the public. Florida has now taken that scrutiny into court.
On 1 October, Attorney General James Uthmeier sued Pfizer and its chief executive, Albert Bourla, alleging deceptive and unfair marketing of the company’s COVID vaccine.
Australia should pay attention. And our authorities should start asking questions of their own.
The complaint challenges two central messages: that the vaccine posed no material safety risks, and that people needed vaccination to prevent transmission to others.
One specific statement deserves examination. The complaint quotes Bourla saying in January 2023: “We’ve seen not a single [safety] signal”. Florida alleges that assurance conflicted with known evidence about myocarditis and pericarditis, particularly among younger males. It also challenges assurances concerning pregnancy and alleges Pfizer promoted protection against transmission despite its original trial not testing that outcome.
The central question is what Pfizer knew when assurances were being made, what evidence supported those assurances, and whether the public was given an accurate account of the risks, limitations, and uncertainties surrounding its product. That question becomes especially serious when governments were using those assurances to justify mandates, employment restrictions and intense social pressure on millions of people.
The original clinical trial was not designed to establish that vaccination prevented transmission. Yet Australians were repeatedly urged to get vaccinated not merely for themselves, but to protect other people. That gap between what had actually been demonstrated and what the public was being told deserves forensic examination.
The same applies to safety. Signals involving myocarditis and pericarditis, particularly among younger males, cannot simply be waved away as inconvenient details. Australians deserve to know when those risks became known, how seriously they were assessed, what Pfizer communicated privately to regulators, and whether public statements accurately reflected the evidence available at the time.
This was not an ordinary consumer transaction. Governments tied vaccination status to employment, movement and participation in ordinary life. When that level of coercive pressure is applied, the standard of honesty demanded from pharmaceutical companies, regulators and politicians should be extraordinarily high. The question is what the evidence supported when each assurance was made.
If the Florida case proceeds into discovery, it could allow lawyers to seek internal safety assessments, correspondence about public statements and records showing how marketing decisions were made. The court will determine the permissible scope, and disclosure to litigants does not guarantee public access.
Still, the prospect matters. An internal assessment written before a television interview can tell us far more than a carefully prepared explanation years afterwards. What did the company know? Who approved the wording? What qualifications were left out?
Australians deserve the same discipline applied here. Whatever qualifications appeared in technical documents, Australians deserve an accounting of the public campaign urging them to get vaccinated to protect themselves and others. Were risks and uncertainties communicated with the same prominence as the assurances? When vaccination became a condition of keeping a job, that obligation became more demanding still. Publishing a warning somewhere does not settle whether the overall message was misleading.
Australia has mechanisms for doing this. The Australian Consumer Law prohibits misleading or deceptive conduct in trade or commerce. The ACCC can receive reports about potentially misleading commercial claims. The TGA also accepts complaints about potentially unlawful therapeutic-goods advertising.
Parliament has a broader responsibility. Committees with the necessary powers can call witnesses and require documents. An inquiry should examine the chain connecting manufacturers, regulators, ministers and the public, with findings published and failures identified.
Then there are the Australians seeking recognition for vaccine injuries. The Commonwealth’s COVID-19 Vaccine Claims Scheme, now closed to new claims, was a compensation mechanism. Its existence never answered the separate question of whether public representations were accurate. The scheme's closure should not close the debate about accountability or adequate support for people harmed.
Florida’s lawsuit will stand or fall on the evidence and the law. Australia need not wait for its outcome before examining our own record.
Publish the assurances. Put the supporting evidence beside them. Require the people responsible to explain any gap.
Australians were asked to trust some very powerful institutions. Those institutions can now submit to scrutiny.
“Trust, but verify.”
– Ronald Reagan
Join 50K+ readers of the no spin Weekly Dose of Common Sense email. It's FREE and published every Wednesday since 2009